Eslicarbazepine acetate is a prodrug of eslicarbazepine (licarbazepine) which is a metabolite of oxcarbazepine. Eslicarbazepine acetate was recently approved in Europe for the treatment of adjunctive therapy for partial-onset of seizures, with or without secondary generalizations, in adults with epilepsy. 9 The mechanism of its action is the inhibition of voltage gated sodium channels in the brain, making brain cells less prone to excitability. The drug was discovered and developed by Bial, a small privately held Portuguese pharmaceutical company, and is marketed in Europe by Eisai Pharmaceutical Co.
Additional Information:
Delivery Time: 1 to 2 days after PO and payment
Packaging Details: 25 kg paking